Medicus Pharma’s (MDCX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note released on Monday morning,Benzinga reports. The firm currently has a $27.00 target price on the stock.

MDCX has been the topic of a number of other research reports. D Boral Capital raised shares of Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th. Wall Street Zen upgraded shares of Medicus Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. Finally, Maxim Group raised their target price on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $23.50.

Medicus Pharma Stock Performance

Shares of NASDAQ MDCX opened at $2.67 on Monday. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $8.94. The company has a 50 day moving average of $4.38 and a 200 day moving average of $3.50.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). On average, sell-side analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling at Medicus Pharma

In other news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of Medicus Pharma stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total transaction of $579,000.00. Following the transaction, the insider now owns 3,248,741 shares in the company, valued at $25,080,280.52. This trade represents a 2.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Hedge Funds Weigh In On Medicus Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new position in Medicus Pharma during the first quarter valued at approximately $211,000. Armistice Capital LLC bought a new position in Medicus Pharma during the first quarter valued at $4,710,000. Finally, Interchange Capital Partners LLC purchased a new position in Medicus Pharma in the fourth quarter worth about $3,628,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.